Syndax Pharmaceuticals (SNDX) Cash & Current Investments (2015 - 2026)

Syndax Pharmaceuticals' Cash & Current Investments history runs 12 years deep, the most recent figure standing at $352.1 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 122.67% year-over-year to $352.1 million in Q1 2026; TTM through Mar 2026 was $352.1 million, a 122.67% increase from a year earlier, with the FY2025 full-year figure at $154.5 million, down 5.83% from the prior year.
• Cash & Current Investments grew to $352.1 million in Q1 2026 per SNDX's latest filing, from $154.5 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $570.7 million in Q4 2023 and bottomed at $63.3 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $158.1 million (2025), against an average of $251.0 million.
• Across the five-year window, Cash & Current Investments sank 84.09% in 2023 and jumped 586.22% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $475.8 million in 2022, then grew by 19.94% to $570.7 million in 2023, then plunged by 71.24% to $164.1 million in 2024, then declined by 5.83% to $154.5 million in 2025, then surged by 127.81% to $352.1 million in 2026.
• Per Business Quant, the three latest SNDX Cash & Current Investments figures stand at $352.1 million (Q1 2026), $154.5 million (Q4 2025), and $135.0 million (Q3 2025).